Dr Khaled H Assi was awarded the PhD in pharmaceutical analysis by the University of Bradford, in 1999. He then took up a postdoctoral post at university of Bradford between 1999-2001 working on the inhaled therapies. His postdoctoral program was extended for one more year through an awarded grant from Glaxo SmithKline. In 2002, he was accepted a research fellowship at Bradford School of Pharmacy. Dr Assi was appointed as a Lecturer at the Bradford School of Pharmacy and then promoted to senior lecturer , in March 2016 and has continued developing his research in the inhaled therapies area. In this position he is teaching the MPharm students at different levels and he is also leading the MSc Pharmaceutical Technology and Medicines Control programme. The modules he delivers cover the area of respiratory drug delivery, pharmaceutical analysis, Quality assurance and quality control of pharmaceuticals. He is also active in the research. His principal research interests lie in the field of drug delivery to the lung, this encompass formulation development for inhalation products. The work involves the development of new formulations for inhaled products including dry powder, nanosuspension and nanoemaulsion for both dry powder inhalers and nebulisers. It also involves selecting a suitable inhalation device for doses of dry powder inhalers and nebulised solutions based on the targeted peripheral lung areas for both locally and systemically acting pharmaceuticals. He also has research interest in the following: o Urinary drug excretion to identify lung and systemic deposition following inhalation. o Evaluate the bioequivalence of inhaled drugs and inhalation techniques. o Determination of the in-vitro characteristics of inhaled products and assessing the in-vitro quality of the dose emitted from inhalation systems (dry powder inhalers [DPIs], metered dose inhalers [MDIs] and nebulisers) and in the determination of the resistance characteristics and comparative product features of various marketed DPIs to identify the optimum inhalation flow rate and appropriate DPI for different patients. In addition to the inhaled therapy I have research in the development of pharmaceutical and bioanalytical assay methods. This includes the optimisation and validation of bioanalytical techniques for qualitative and quantitative determination of inhaled drugs and its metabolites in aqueous and biological fluids for bioequivalence and pharmacokinetic studies.